“Harke Group started very early, around end of the 90s, with the process of digital transformation, so that we can meanwhile look back to almost two decades of experience in this area. We therefore see for us rather chances than risks in it.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International